Renew Biotechnologies Unites Wasatch BioLabs and Resonant for Enhanced Diagnostic Solutions
In a move aimed at streamlining its operations and enhancing its capabilities in the rapidly evolving field of molecular diagnostics, Renew Biotechnologies has announced the unification of its subsidiaries - Wasatch BioLabs and Resonant - under the Renew Biotechnologies brand. This strategic decision, communicated on July 9, 2026, marks a significant milestone in the organization's pursuit of advancing sequencing-based diagnostics and translational research.
The consolidation is designed to provide clients, stakeholders, and partners with a more streamlined access to an integrated suite of services that encompass advanced sequencing, assay development, diagnostic product development, and laboratory infrastructure. Given the increasing demand for precise and actionable biological insights, the move comes at a critical time in the biotech landscape, as researchers and clinicians seek to utilize advanced methodologies to tackle complex diseases.
Chad Pollard, CEO and Co-founder of Renew Biotechnologies, articulated the company's vision for the unification, stating, "Renew Biotechnologies is building a platform designed to make complex biology more measurable, actionable, and clinically useful." He emphasized that this transition is more than administrative—it is about better articulating the company's capabilities and accelerating innovation to deliver clinical impact through advanced molecular technologies.
Importantly, this is not an acquisition, merger, or change in management structure. Renew Biotechnologies has consistently been the parent company of both Wasatch BioLabs and Resonant. Therefore, existing services, projects, contracts, and customer relationships will proceed without disruption, but now under a more cohesive brand identity.
Wasatch BioLabs has been recognized since its inception in 2022 for its pioneering work in long-read and native-read sequencing, along with custom assay development and translational research. In parallel, Resonant has focused on sequencing-based diagnostic innovations, notably its NeuroLens®, a cutting-edge liquid biopsy test intended for measuring neuron-associated cell death through circulating cell-free DNA methylation signals—crucial for the diagnosis of conditions like Alzheimer's Disease.
By merging their strengths, Renew Biotechnologies now offers a comprehensive platform that facilitates partners' journey from biomarker discovery to diagnostic product development, through assay validation and into clinical application.
Steve Abbott, Chief Operating Officer of Renew Biotechnologies, further elaborated on the advantages of this consolidation, stating, "This reflects the company we've built. By integrating our laboratory infrastructure, technology development, clinical operations, and product programs under one umbrella, we're ensuring a clearer path for developing and validating advanced molecular technologies for real-world research and clinical utility."
Looking ahead, the consolidated brand will continue to expand its offerings across various domains such as long-read and native-read sequencing, RNA therapeutic quality control, methylation technologies, pharmacogenomics, telomere sequencing, blood-based diagnostics, and customized assay development.
To facilitate this transition, Renew Biotechnologies has launched a new website that serves as a hub for all its services relating to sequencing, clinical laboratory capabilities, and partnership opportunities. The aim is to provide a unified point of contact that aligns with the enhanced brand identity.
For those interested in exploring these advancements in sequencing technology and diagnostics, more information is readily available at Renew Biotechnologies' new website.
In summary, this brand consolidation represents a strategic evolution for Renew Biotechnologies, allowing it to clearly define its mission and offerings in a complex biotech landscape. As the company forges ahead under a single brand identity, it is well-poised to continue its leadership role in the development of innovative diagnostic solutions that promise to make a significant difference in patient care and clinical outcomes.
The consolidation is designed to provide clients, stakeholders, and partners with a more streamlined access to an integrated suite of services that encompass advanced sequencing, assay development, diagnostic product development, and laboratory infrastructure. Given the increasing demand for precise and actionable biological insights, the move comes at a critical time in the biotech landscape, as researchers and clinicians seek to utilize advanced methodologies to tackle complex diseases.
Chad Pollard, CEO and Co-founder of Renew Biotechnologies, articulated the company's vision for the unification, stating, "Renew Biotechnologies is building a platform designed to make complex biology more measurable, actionable, and clinically useful." He emphasized that this transition is more than administrative—it is about better articulating the company's capabilities and accelerating innovation to deliver clinical impact through advanced molecular technologies.
Importantly, this is not an acquisition, merger, or change in management structure. Renew Biotechnologies has consistently been the parent company of both Wasatch BioLabs and Resonant. Therefore, existing services, projects, contracts, and customer relationships will proceed without disruption, but now under a more cohesive brand identity.
Wasatch BioLabs has been recognized since its inception in 2022 for its pioneering work in long-read and native-read sequencing, along with custom assay development and translational research. In parallel, Resonant has focused on sequencing-based diagnostic innovations, notably its NeuroLens®, a cutting-edge liquid biopsy test intended for measuring neuron-associated cell death through circulating cell-free DNA methylation signals—crucial for the diagnosis of conditions like Alzheimer's Disease.
By merging their strengths, Renew Biotechnologies now offers a comprehensive platform that facilitates partners' journey from biomarker discovery to diagnostic product development, through assay validation and into clinical application.
Steve Abbott, Chief Operating Officer of Renew Biotechnologies, further elaborated on the advantages of this consolidation, stating, "This reflects the company we've built. By integrating our laboratory infrastructure, technology development, clinical operations, and product programs under one umbrella, we're ensuring a clearer path for developing and validating advanced molecular technologies for real-world research and clinical utility."
Looking ahead, the consolidated brand will continue to expand its offerings across various domains such as long-read and native-read sequencing, RNA therapeutic quality control, methylation technologies, pharmacogenomics, telomere sequencing, blood-based diagnostics, and customized assay development.
To facilitate this transition, Renew Biotechnologies has launched a new website that serves as a hub for all its services relating to sequencing, clinical laboratory capabilities, and partnership opportunities. The aim is to provide a unified point of contact that aligns with the enhanced brand identity.
For those interested in exploring these advancements in sequencing technology and diagnostics, more information is readily available at Renew Biotechnologies' new website.
In summary, this brand consolidation represents a strategic evolution for Renew Biotechnologies, allowing it to clearly define its mission and offerings in a complex biotech landscape. As the company forges ahead under a single brand identity, it is well-poised to continue its leadership role in the development of innovative diagnostic solutions that promise to make a significant difference in patient care and clinical outcomes.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.